Trial Profile
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluciclatide F-18 (Primary)
- Indications Tumours
- Focus Biomarker; Diagnostic use
- Sponsors GE Healthcare
- 30 Apr 2014 New trial record